Sight Sciences, Inc. (SGHT) · Nov 4, 2026 · Earnings

Sight Sciences earnings beat as dry eye drives guidance raise

Beat — Q3 revenue $24.9M vs ~$23.51M consensus

Sight Sciences earnings beat revenue expectations, with rapid TearCare growth helping lift 2026 guidance while cash usage improves.

Sight Sciences is rebuilding growth around two interventional eye-care franchises: OMNI for glaucoma and TearCare for reimbursed dry-eye treatment. The prior setup already pointed to a recovery—management had raised 2026 revenue guidance to $88M-$92M in August while cutting adjusted operating-expense guidance to $92M-$94M.

The quarter clearly beat the published revenue bar. Q3 revenue reached $24.9M, up 25% year over year, versus published consensus of approximately $23.51M, or roughly 6% above expectations. The company also described this as its third straight quarter of double-digit growth.

MetricQ3 2026 / FY26ComparisonConsensus / Prior guide
Revenue (Financial Highlights)$24.9M (+25%)$19.9M implied~$23.51M
FY revenue guidance (FY Guidance)$92M-$93M—$88M-$92M
FY adjusted OpEx guidance (FY Guidance)$92M-$94M—$92M-$94M
YTD glaucoma revenue (Financial Highlights)$60.1M (+7%)——
YTD dry-eye revenue (Financial Highlights)$7.9M$0.9M prior year—

The guidance increase is the more important signal than the quarterly beat. Full-year revenue guidance moved to $92M-$93M from $88M-$92M, implying the company now expects to finish above the previous midpoint despite keeping its expense outlook unchanged.

TearCare is becoming a real growth engine rather than a small add-on. Interventional dry-eye revenue reached $7.9M year to date versus $0.9M a year earlier, while glaucoma revenue grew a more modest 7%. That mix matters because the company is no longer relying solely on the mature OMNI franchise to restart growth; it is beginning to show commercial traction from the reimbursed dry-eye market after the October 2025 Medicare fee-schedule changes.

The growth came with better cash discipline, improving the quality of the result. Management said cash usage improved 74% year over year and adjusted operating expenses were 99% of year-to-date revenue versus 121% in the prior year. That does not establish profitability, but it shows the company is scaling commercial investment without repeating the earlier cash-burn profile. 〔0〕

Bottom line: This was more than an expected recovery quarter: revenue beat the market's bar, dry eye is scaling rapidly, and the full-year revenue guide moved higher without higher expense guidance. The business story is strengthening, though the event advances the existing turnaround rather than completely rewriting it.

What to watch next

Q4 2026 results and 2027 outlook

Original filing on SEC EDGAR

Sight Sciences earnings beat as dry eye drives guidance raise | SGHT Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.